A Arti 60mg Injection

This injectable medication is specifically formulated for the urgent treatment of severe malaria, particularly when caused by Plasmodium falciparum. It acts quickly to reduce parasite load in the bloodstream, offering a critical intervention for patients unable to take oral medication. Its fast action helps manage life-threatening complications associated with advanced malarial infection.

Artemether, the active ingredient, is a potent artemisinin derivative. It works by forming highly reactive free radicals within the malaria parasites, primarily in the food vacuole. These free radicals damage parasite proteins and membranes, leading to rapid parasite death and effective clearance from the blood.

• Preparation: A Arti 60mg Injection must be administered by a qualified healthcare professional, typically via intramuscular injection.
• Timing: The treatment usually begins with an initial loading dose, followed by maintenance doses as prescribed.
• Frequency: Your doctor will determine the precise schedule, often involving daily injections for a specific duration.
• Food Interaction: Administration of this injection is independent of food intake.
• Completion: It is critical to complete the entire course of treatment as directed, even if symptoms improve.
• Monitoring: Patients will be closely monitored by medical staff throughout and after the administration of the injection.

• A Arti 60mg Injection is not recommended during the first trimester of pregnancy unless absolutely essential and the potential benefits significantly outweigh the risks.
• Use with caution in patients with severe hepatic or renal impairment; dose adjustment may be necessary under medical supervision.
• Close monitoring is required for patients with pre-existing neurological conditions due to potential neurological side effects.
• Do not administer if there is a known hypersensitivity to artemether or other artemisinin derivatives.
• Ensure a full course of treatment is completed to prevent recurrence of malaria and the development of drug resistance.

Absolute: Documented hypersensitivity or severe allergic reaction to artemether or other artemisinin compounds | Relative: First trimester of pregnancy (use only if no safer alternative), severe pre-existing neurological disorders, severe liver dysfunction.

Common (mild, pass quickly): Injection site pain or swelling, nausea, vomiting, dizziness, headache, abdominal pain, diarrhea | Serious (seek help): Severe allergic reactions (e.g., rash, intense itching, significant swelling of face/throat/tongue, severe dizziness, difficulty breathing), neurological disturbances (e.

g., seizures, gait instability, confusion), cardiac abnormalities, significant decrease in blood cell counts (anemia, leukopenia).

CYP3A4 Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine): May decrease artemether plasma levels, potentially reducing the efficacy of A Arti 60mg Injection | CYP3A4 Inhibitors (e.

g., Ketoconazole, Ritonavir): May increase artemether plasma levels, potentially enhancing side effects | Other Antimalarials: Use with caution; potential for additive effects or altered pharmacokinetics | Mefloquine: Administer A Arti 60mg Injection at least 12 hours after mefloquine to avoid potential cardiotoxicity.

Storage: Store A Arti 60mg Injection vials in their original packaging at room temperature (15-30°C), protected from direct light. Do not freeze | Disposal: Unused medication and expired vials should be returned to a pharmacy or disposed of according to local biomedical waste guidelines. Do not dispose of in household trash or wastewater.